

Financial news for HRTX dated on 2020-06-04: Heron Therapeutics Highlights Publication Of Results From Phase 2b Study Of HTX-011 In Patients Undergoing Total Knee Arthroplasty

Financial news for HRTX dated on 2020-05-27: Guggenheim Initiates Coverage On Heron Therapeutics with Buy Rating, Announces Price Target of \$24

Financial news for HRTX dated on 2020-05-18: Heron Therapeutics Announces Initiation of Phase 1b/2 Clinical Study of HTX-034 for the Treatment of Postoperative Pain

Financial news for HRTX dated on 2020-03-02: Needham Maintains Buy on Heron Therapeutics, Lowers Price Target to \$44

Financial news for HRTX dated on 2020-03-02: Heron Therapeutics Q4 EPS \$(0.65) Down From \$(0.63) YoY, Sales \$35.083M Up From \$28.844M YoY

Financial news for HRTX dated on 2020-02-20: Needham Maintains Buy on Heron Therapeutics, Lowers Price Target to \$48

Financial news for HRTX dated on 2020-02-19: Heron Therapeutics shares are trading lower after the company announced the FDA extended the review period for the NDA for HTX-011.

Financial news for HRTX dated on 2020-02-19: Heron Therapeutics Announces FDA Extension of Review Period For NDA For HTX-011

Financial news for HRTX dated on 2020-01-22: Heron Therapeutics shares are trading higher. Not currently seeing any company-specific news.

Financial news for HRTX dated on 2020-01-13: Heron Therapeutics Highlights Progress In Pain Management And CINV Franchises

Financial news for HRTX dated on 2019-12-16: Heron Therapeutics Highlights Publication Of Mechanism Of Action Data For HTX-011, A Dual-Acting Local Anesthetic Being Developed For Management of Postoperative Pain

Financial news for HRTX dated on 2019-12-03: Health Canada Grants Priority Review Status for Heron Therapeutics' New Drug Submission for HTX-011 for Management of Postoperative Pain

Financial news for HRTX dated on 2019-11-12: Heron Therapeutics Q3 EPS \$(0.42) Up From \$(0.49) YoY, Sales \$42.6M Up From \$19.786M YoY

Financial news for HRTX dated on 2019-10-28: Heron Therapeutics Announces FDA Acceptance Of New Drug Application Resubmission For HTX-011 For Management Of Postoperative Pain

Financial news for HRTX dated on 2019-10-22: Heron Announces FDA Approval of Supplemental New Drug Application To Expand CINVANTI Label For Single-Dose Regimen For Patients Receiving Moderately Emetogenic Chemotherapy

Financial news for HRTX dated on 2019-10-04: Heron Therapeutics Late Thursday Priced 8.571M Shares At \$17.50/Share

Financial news for HRTX dated on 2019-10-04: Heron Therapeutics shares are trading lower after the company announced a common stock offering with no size disclosed.

Financial news for HRTX dated on 2019-10-03: Heron Therapeutics shares are trading lower after the company announced a common stock offering with no size disclosed.

Financial news for HRTX dated on 2019-10-03: Heron Therapeutics Reports Offering Of Common Stock, No Size Disclosed

Financial news for HRTX dated on 2019-10-03: JMP Securities Reiterates Market Outperform on Heron Therapeutics, Lowers Price Target to \$32

Financial news for HRTX dated on 2019-10-02: Heron Announces Topline Results From Phase 3b Clinical Study Of HTX-011 In Total Knee Arthroplasty

Financial news for HRTX dated on 2019-10-01: Heron Therapeutics Resubmits New Drug Application To FDA For HTX-011 For The Management Of Postoperative Pain

Financial news for HRTX dated on 2019-08-20: Heron Therapeutics Highlights Publication Of Results From EPOCH 2 Phase 3 Study Of HTX-011 In Patients Undergoing Hernia Repair Surgery

Financial news for HRTX dated on 2019-08-05: Heron Therapeutics Q2 EPS \$(0.63) Down From \$(0.54) YoY, Sales \$36.7M Up From \$17.277M YoY

Financial news for HRTX dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for HRTX dated on 2019-06-28: Heron Therapeutics Shares Up 1% To Session High; Hearing Cowen Said Form 483S Filed With FDA Indicates CMC Issues Are Resolvable

Financial news for HRTX dated on 2019-05-21: Heron Therapeutics Highlights Publication Of Results From Phase 3 EPOCH 1 Study Of HTX-011 In Patients Undergoing Bunionectomy

Financial news for HRTX dated on 2019-05-14: Heron Therapeutics Reports Presentation Of New Results From Study Showing 95% of Postoperative Patients Remain Opioid-Free when HTX-011 Is Given with an Over-the-Counter Analgesic Regimen

Financial news for HRTX dated on 2019-05-09: Heron Therapeutics Q1 EPS \$(0.8) Misses \$(0.49) Estimate, Sales \$31.6M Beat \$28.04M Estimate

Financial news for HRTX dated on 2019-05-07: Heron Therapeutics Reports Partnership with National Academy Of Medicine's Action Collaborative On Countering US Opioid Epidemic

Financial news for HRTX dated on 2019-05-02: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Thurs., May 1, 2019

Financial news for HRTX dated on 2019-05-01: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wed., May 1, 2019

Financial news for HRTX dated on 2019-05-01: Heron Therapeutics shares are trading lower after the FDA rejected the company's marketing application for a pain treatment.

Financial news for HRTX dated on 2019-05-01: Heron Therapeutics is trading lower after the company reported it received a Complete Response Letter from the FDA for its post-operative pain drug candidate.

Financial news for HRTX dated on 2019-05-01: Heron Therapeutics Shares Resume Trade, Down 31.5%

Financial news for HRTX dated on 2019-05-01: Pacira Biosciences Shares Spike ~12% Premarket Following Complete Response Letter From Heron Therapeutics For Its Postoperative Pain Treatment; BZ NOTE: Pacira Has A Competing Drug Candidate

Financial news for HRTX dated on 2019-05-01: UPDATE: Heron Says Plans To Request FDA Meeting To Obtain Deal On Co.'s Approach To Resolve Issues Outlined By FDA's CRL

Financial news for HRTX dated on 2019-05-01: UPDATE: Heron Says 'No Clinical Safety or Efficacy Issues Identified, and No Requirement for Further Clinical Data'

Financial news for HRTX dated on 2019-05-01: Heron Therapeutics Shares To Resume Trade At 8:30 a.m. EDT

Financial news for HRTX dated on 2019-05-01: Heron Therapeutics Reports Received Complete Response Letter For HTX-011

Financial news for HRTX dated on 2019-05-01: Heron Therapeutics Shares Halted News Pending

Financial news for HRTX dated on 2019-04-01: Heron Therapeutics Announces its Marketing Authorization Application for HTX-011 Was Approved by the European Medicines Agency

Financial news for HRTX dated on 2019-03-11: Heron Therapeutics Gives an Update on HTX-011

Financial news for HRTX dated on 2019-02-26: Heron Therapeutics Reports FDA Approval Of Supplemental New Drug Application To Expand CINVANTI Label For IV Push

Financial news for HRTX dated on 2019-02-22: Heron Therapeutics Q4 EPS \$(0.63) Misses \$(0.46) Estimate, Sales \$28.8M Beat \$26.93M Estimate

Financial news for HRTX dated on 2019-02-05: Heron Therapeutics Reports Pres Robert Rosen To Retire; CEO Barry Quart Will Take On Added Role Of Pres

Financial news for HRTX dated on 2019-01-07: Heron Therapeutics Announces a PDUFA Date of April 30th, 2019 For HTX-011

Financial news for HRTX dated on 2019-01-07: Heron Therapeutics Sees FY2018 Sales \$76.70M vs \$72.41M Est

Financial news for HRTX dated on 2019-01-07: Heron Therapeutics Sees Q4 Sales \$28.10M vs \$23.72M Est

Financial news for HRTX dated on 2019-01-03: Heron Therapeutics Announces Study Results Showing 90% Of Patients Remained Opioid-Free When Its HTX-011 Was Given With An Over-the-Counter Analgesic Regimen

Financial news for HRTX dated on 2018-12-31: Heron Therapeutics shares are trading higher after the FDA granted priority review designation for its new drug application for HTX-011.

Financial news for HRTX dated on 2018-12-31: Heron Therapeutics Reports FDA Granted Priority Review Designation For Its New Drug Application For HTX-011

Financial news for HRTX dated on 2018-11-07: Heron Therapeutics Q3 EPS \$(0.49) Misses \$(0.45) Estimate, Sales \$19.786M Beat \$19.09M Estimate

Financial news for HRTX dated on 2018-10-31: Heron Submits a New Drug Application to the FDA for HTX-011

Financial news for HRTX dated on 2018-09-14: Stifel Nicolaus Initiates Coverage On Heron Therapeutics with Buy Rating, Announces \$55 Price Target

Financial news for HRTX dated on 2018-08-08: Heron Therapeutics Q2 EPS \$(0.54) Beats \$(0.70) Estimate

Financial news for HRTX dated on 2018-07-19: Cantor Fitzgerald Maintains Overweight on Heron Therapeutics, Raises Price Target to \$50

Financial news for HRTX dated on 2018-06-26: Heron Therapeutics Prices \$200M Public Offering of Common Stock; Price Not Disclosed

Financial news for HRTX dated on 2018-06-25: Heron Therapeutics Announces \$200M Common Stock Offering

Financial news for HRTX dated on 2018-06-22: Oppenheimer Maintains Outperform on Heron Therapeutics, Raises Price Target to \$50

Financial news for HRTX dated on 2018-06-21: Heron Therapeutics Option Alert: Jul 20 \$33 Puts Sweep (2) near the Bid: 1143 @ \$0.401 vs 2955 OI; Earnings 8/8 After Close [est] Ref=\$40.05

Financial news for HRTX dated on 2018-06-21: Evercore Raises Heron Therapeutics Price Target From \$56 To \$80 And Remains A Top Pick Following '011 P2b Data That Was 'Rock Solid'

Financial news for HRTX dated on 2018-06-21: Shares of Heron Therapeutics Up 27.8%, Traders Circulating Chatter That Evercore Increased Co.'s Price Target To \$80

Financial news for HRTX dated on 2018-06-21: Heron Therapeutics Reports HTX-011 for Postoperative Pain Management Receives Breakthrough Therapy Designation from FDA Conference Call and Webcast Today at 8:30 a.m. ET

Financial news for HRTX dated on 2018-06-05: Jefferies Global Healthcare Begins Today, Presenters Include: Kadmon, Aeri Pharma, Chemed, Orthofix, Revance, Heron Therapeutics, and Dicerna Pharma

Financial news for HRTX dated on 2018-05-10: Heron Therapeutics Q1 EPS \$(0.81) Beats \$(0.86) Estimate, Sales \$11.6M Beat \$11.24M Estimate

Financial news for HRTX dated on 2018-04-05: Evercore Out Positive On Heron Therapeutics, Gives Bullish Scenario Of \$150/Share If HTX-011 Is Rapidly Adopted By Hospital Pharmacies & Committees, Is Able To Expand Into Low Vol. Procedures, And Is Able To Reduce Hospitalization Duration Post-Procedures

Financial news for HRTX dated on 2018-03-28: Heron Therapeutics Announces Common Stock Offering, No Size Disclosed

Financial news for HRTX dated on 2018-03-20: Benzinga Pro's Most-Searchd Tickers For Tues., Mar. 20

Financial news for HRTX dated on 2018-03-19: Benzinga Pro's Top 10 Most-Searchd Tickers For Mon., Mar. 19

Financial news for HRTX dated on 2018-03-19: Heron Therapeutics Shares Up 24.9% On News Phase 3 Trial Of HTX-011 Met All Primary, Key Secondary Endpoints

Financial news for HRTX dated on 2018-03-19: Heron Therapeutics' Phase 3 Trial of HTX-011 Met all Primary and Key Secondary Endpoints

Financial news for HRTX dated on 2018-02-27: Heron Therapeutics Reports Q4 EPS \$(1.09) vs \$(0.79) Est., Net Product Sales Of SUSTOL \$10.1M vs \$9.3M Est.

Financial news for HRTX dated on 2018-02-14: Leerink Partners Global Healthcare Conference Begins Today, Presenters Include: Dova Pharma, Heron Therapeutics, Sage Therapeutics, Enanta, The Medicines Company, Puma Biotech, Dicerna Pharma, Biogen, bluebird bio, and Alexion Pharma

Financial news for HRTX dated on 2018-01-08: Heron Therapeutics Earlier Reported Prelim. Q4 SUSTOL Sales \$10M, FY17 SUSTOL Sales \$31M Above Guidance OF \$25M-\$30M; Sees FY18 CINV Net Sales \$60M-\$70M

Financial news for HRTX dated on 2018-01-03: Leerink Swann Initiates Coverage On Heron Therapeutics with Outperform Rating, Announces \$22.00 Price Target

Financial news for HRTX dated on 2017-12-04: Heron Therapeutics Reports Public Offering of Common Stock, Terms Not Disclosed

Financial news for HRTX dated on 2017-11-16: Jefferies 2017 London Healthcare Conference Concludes Today, Presenters Include: Ignyta, Heron Therapeutics, and TherapeuticsMD

Financial news for HRTX dated on 2017-11-09: Heron Therapeutics Shares, Previously Halted, Have Resumed, Now Down 0.29% After Hours

Financial news for HRTX dated on 2017-11-09: Heron Therapeutics Announces U.S. FDA Approval of CINVANTI

Financial news for HRTX dated on 2017-11-06: Heron Therapeutics Reports Q3 EPS \$(0.77) vs \$(0.86) Est., Sales \$8.572M vs \$8.22M Est.

Financial news for HRTX dated on 2017-10-31: Oppenheimer Initiates Coverage On Heron Therapeutics with Outperform Rating, Announces \$27.00 Price Target

Financial news for HRTX dated on 2017-09-27: Northland Securities Initiates Coverage On Heron Therapeutics with Outperform Rating

Financial news for HRTX dated on 2017-09-27: Mizuho Initiates Coverage On Heron Therapeutics with Buy Rating, Announces \$28.00 Price Target

Financial news for HRTX dated on 2017-09-25: Cantor Fitzgerald Global Healthcare Conference Begins Today, Presenters Include: Verastem, Advaxis, Exelixis, Heron Therapeutics, and Enanta Pharma

Financial news for HRTX dated on 2017-08-09: Heron Therapeutics Initiates Phase 3 Program For HTX-011 After Successful FDA Meeting

Financial news for HRTX dated on 2017-08-09: Heron Therapeutics Reports Q2 EPS \$(0.80) vs \$(0.92) Est., Sales \$8.5M vs \$5.5M Est.

Financial news for HRTX dated on 2017-07-06: Heron Therapeutics Files For Potential Mixed Shelf, No Size Disclosed

Financial news for HRTX dated on 2017-06-06: Jefferies Health Care Conference Begins Today, Presenters Include: Agilent Technologies, Civitas Solutions, Aeri Pharmaceuticals, Alkermes, Alnylam Pharmaceuticals, Heron Therapeutics

Financial news for HRTX dated on 2017-05-10: Heron Therapeutics Reports Q1 EPS \$(1.00) vs \$(0.91) Est., Net Product Sales of SUSTOL \$3.6M vs \$2.6M Est.

Financial news for HRTX dated on 2017-04-24: Heron Therapeutics Names Robert E. Hoffman as CFO

Financial news for HRTX dated on 2017-02-27: Needham Initiates Coverage On Heron Therapeutics With Buy, Announces \$28 Price Target

Financial news for HRTX dated on 2017-02-23: Heron Therapeutics Reports Q4 EPS \$(1.22) vs \$(1.17) Est., Sales \$1.279B vs \$1.09B Est.

Financial news for HRTX dated on 2017-01-19: Heron Therapeutics Files 12.3M Share Offering at \$12.20/Share

Financial news for HRTX dated on 2017-01-18: Filing from Heron Therapeutics Shows Registration for \$150M Common Stock Offering

Financial news for HRTX dated on 2017-01-12: Heron Announces Submission of CINVANTI NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting

Financial news for HRTX dated on 2017-01-04: Adam Feuerstein Tweets: \$HRTX forecasts Sustol net sales of \$15-25M in 2017. Current consensus is \$46.5M, per FactSet.

Financial news for HRTX dated on 2017-01-04: Heron Therapeutics Reports Synergy of Bupivacaine and Meloxicam with HTX-011 for Prevention of Post-Operative Pain in Phase 2 Clinical Studies

Financial news for HRTX dated on 2016-10-26: Aegis Capital Initiates Coverage On Heron Therapeutics, Inc. - Common Stock at Buy, Announces \$41.00

Financial news for HRTX dated on 2016-10-04: Brean Capital Assumes Heron Therapeutics at Buy, Announces \$41.00 PT

Financial news for HRTX dated on 2016-09-06: Lake Street Assumes Heron Therapeutics at Buy, Announces \$45.00 PT

Financial news for HRTX dated on 2016-05-02: Cantor Fitzgerald Initiates Coverage on Heron Therapeutics at Buy, Announces \$41.00 PT

Financial news for HRTX dated on 2015-12-10: Lake Street Capital Initiated Coverage on Heron Therapeutics at Buy, Announced \$45.00 PT Before the Open

Financial news for HRTX dated on 2015-09-22: Heron Therapeutics to Present Data From Completed Phase 3 MAGIC Study of SUSTOL at ASCO

Financial news for HRTX dated on 2015-09-02: Bank of America Initiates Coverage on Heron Therapeutics at Buy, Announces \$46.00 PT

Financial news for HRTX dated on 2015-06-26: Cowen & Company Initiates Coverage on Heron Therapeutics at Outperform, Announces \$40.00 PT

Financial news for HRTX dated on 2015-03-20: Jefferies Initiates Coverage on Heron Therapeutics at Buy

Financial news for HRTX dated on 2015-03-19: Heron Therapeutics Announces Positive Results From Phase 1 Study of HTX-011

Financial news for HRTX dated on 2014-08-07: Noble Financial Initiates Coverage on Heron Therapeutics Inc at Buy, Announces \$18.00 PT

Financial news for HRTX dated on 2014-08-04: Heron Therapeutics Inc Reports Q2 EPS of \$(0.78) vs \$(0.74) Est

Financial news for HRTX dated on 2014-06-25: Morning Market Losers

Financial news for HRTX dated on 2014-06-25: Heron Therapeutics Prices 4.5M Share Offering at \$11.74/Share

Financial news for HRTX dated on 2014-06-24: Heron Therapeutics Announces Proposed Secondary

Financial news for HRTX dated on 2014-06-19: 8-K from Heron Therapeutics Shows COO Davis Will Step Down

Financial news for HRTX dated on 2014-06-02: Heron Therapeutics Offers Update on SUSTOL Program, Says Now Plans to Include Delayed-HEC in NDA Resubmission

Financial news for HRTX dated on 2014-05-14: Heron Therapeutics Announces Positive Results for HTX-011

Financial news for HRTX dated on 2014-05-13: Heron Therapeutics Files \$100M Mixed Securities Shelf

Financial news for HRTX dated on 2014-03-31: Heron Therapeutics Initiates Phase 3 Label Expansion Study of SUSTOL